Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


April 19, 2015 1:52 AM ET

Pharmaceuticals

Company Overview of Aesica Pharmaceuticals Limited

Company Overview

Aesica Pharmaceuticals Limited provides pharmaceutical contract development and manufacturing services. The company offers potency drug substance and drug manufacturing services that include the production of highly potent active pharmaceutical ingredients; formulation development, analytics, and GMP services for pharmaceutical dosage forms that include tablets, capsules, liquids, suspensions, creams, ointments, and inhaled pharmaceuticals; and finished dose manufacturing services, such as wet granulation, tablet production, encapsulation, liquid manufacturing, temperature critical, blister packaging, and bottle packing. It serves pharmaceutical, biotech, and life science companies, as well ...

Q5

Quorum Business Park

Benton Lane

Newcastle upon Tyne,  NE12 8BS

United Kingdom

Founded in 2004

Phone:

44 19 1218 1960

Fax:

44 19 1266 9447

Key Executives for Aesica Pharmaceuticals Limited

Managing Director
Chief Financial Officer
Chief Operations Officer and Managing Director of API
Head of Quality - Cramlington Facility
Group Marketing and Communications Director
Compensation as of Fiscal Year 2014.

Aesica Pharmaceuticals Limited Key Developments

Aesica Announces Board Appointments

Aesica announced the appointment of two senior business development positions. Detlef Behrens has been appointed to the role of Vice President, Business Development, Finished Dose with Sven Wrabletz joining as Business Development Director, Finished Dose. Detlef has overall responsibility for business development and for finished dose services, covering formulation development, bulk manufacturing and packaging with a full international remit across the Group. Sven is also responsible for finished dose development, manufacturing and packaging but with a geographic remit covering Northern Germany, Benelux and Eastern Europe. Both positions are based in Germany. Detlef reports directly to Ian Muir, Managing Director, Finished Dose and prior to working for Aesica, Detlef held senior BD roles at Piramal and Next Pharma. Sven Wrabletz reports to Detlef Behrens.

Aesica Introduces 3P’s Fill2Weight Dispensing System

Aesica has introduced 3P’s Fill2Weight dispensing system – suitable for all powder formulations including spray dried and lyophilised powders – to its Nottingham site, enabling increased flexibility and reduced time in ‘first in human’ clinical studies. The Fill2Weight system is widely acknowledged as the most flexible micro dosing system available to the market, with the technology able to dose a wide range of powders and can quickly be scaled up from clinical to commercial production. Aesica will be offering the system to customers as a tool that enables the direct filling of APIs in to capsules, syringes or bottles, eliminating the time and cost associated with developing a blended formulation. Developed to fill a target weight, rather than dispensing fixed volume, Fill2Weight dynamically measures and records the dispensed weight of all doses, allowing for compensation in powder property changes without the need for intervention or re-calibration. The flexibility offered by the platform means that the micro dosing system can be used across capsules, vials, blisters, injectables or inhalers and weighting resolutions as low as 10 µg (10x lower than the competitor). Consequently, Fill2Weight is usable with potent compounds. With the increased drive from clients and regulatory bodies for Quality by Design (QbD), the micro dosing system’s flexibility and repeatability ensures that experiments can be designed from laboratory scale right through to commercial supply, due to the platform’s modular design. Moreover, multi-track production settings limit process changes in the final stages of product development and provide tighter regulation of process controls. Quality is enhanced with reduced weight variability, lower rejection levels and 100% weight recording, meaning the system is suitable for real-time release, monitoring and recording. The system is configurable for doses between 2.5mg-500mg, with a dosing accuracy of <3% RSD and cycle feed times of less than two seconds. The 3P Fill2Weight can be fully sterilised which allows it to be used to aseptically fill re-constitutable powders in to bottles or syringes. This delivers a cost-effective, truly scalable alternative to ‘in-vial’ lyophilisation.

Aesica Announces £30 Million Expansion at Queenborough Manufacturing Site

Aesica announced the creation of a new high capacity manufacturing facility following a £30 million investment at its Queenborough, Kent site. The 10,000 sq. m expansion has been constructed for the production of dose medication used in treating one of the most common lifestyle diseases: Type 2 diabetes in adults. The commercial production at the facility will commence in November. This development will approximately double the site’s solid dose manufacturing capacity and represents a major investment in highly technical and specialist equipment. The facility will have a dedicated workforce of 55 technicians with the design of the facility allowing the current capacity to be more than doubled in the future, which would require a further additional 50 staff to be recruited.

Similar Private Companies By Industry

Company Name Region
ECO Animal Health Ltd. Europe
Funxional Therapeutics Ltd. Europe
Phusion Healthcare Limited Europe
Pharmacia Ltd. Europe
Amdipharm UK Limited Europe

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Aesica Pharmaceuticals Limited, please visit www.aesica-pharma.co.uk. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.